

# **Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients**

Oct 08, 2018

---

**Source URL:** <https://qa1.novartis.us/news/media-releases/novartis-announces-fda-filing-acceptance-siponimod-baf312-first-and-only-oral-drug-shown-delay-disability-progression-typical-spms-patients-0>

## **List of links present in page**

1. <https://qa1.novartis.us/news/media-releases/novartis-announces-fda-filing-acceptance-siponimod-baf312-first-and-only-oral-drug-shown-delay-disability-progression-typical-spms-patients-0>